TreeFrog Therapeutics
Stem cell company that will enable millions of patients to access the medical revolution of cell.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Late VC | |
| Total Funding | 000k | ||
Related Content
TreeFrog Therapeutics is a French biotechnology company specializing in cell therapy. The company has developed a proprietary technology called C-Stem, which enables the mass production of high-quality stem cells. This technology addresses a major challenge in the field of cell therapy, which is the ability to produce large quantities of cells for clinical and commercial use.
The company's business model is based on developing its own pipeline of cell therapies and collaborating with other companies in the field. TreeFrog Therapeutics is currently focused on developing treatments for neurodegenerative diseases, such as Parkinson's disease, and has a pipeline of therapeutic candidates in preclinical development. The company operates in the regenerative medicine market, which is a rapidly growing segment of the healthcare industry.
TreeFrog Therapeutics serves a variety of clients, including pharmaceutical and biotechnology companies, as well as academic research institutions. The company's C-Stem technology is available for licensing, and TreeFrog Therapeutics also provides cell manufacturing services to its partners.
Keywords: cell therapy, stem cells, regenerative medicine, biotechnology, C-Stem, neurodegenerative diseases, Parkinson's disease, cell manufacturing, preclinical development, licensing.